Holen Sie sich die Stockscreener-App
9.39
0.11%
-0.010
Handel nachbörslich:
9.39
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - FinancialContent
Amneal Will End Sale of Calcium-Drip Copies in Patent-Suit Pact - Bloomberg Law News
Amneal Pharmaceuticals Insider Sold Shares Worth $302,596, According to a Recent SEC Filing - MarketScreener
Here's Why Momentum in Amneal (AMRX) Should Keep going - Yahoo Finance
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - TradingView
Is Amneal Pharmaceuticals Inc. forming a bullish divergenceGuaranteed Profit Setup Watchlist - newsyoung.net
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - MSN
Brown Rudnick Represents Amneal Pharmaceuticals LLC in a $2.1 Billion Term Loan Credit Facility - Brown Rudnick
‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs - insights.citeline.com
Amneal Pharmaceuticals Inc. Stock Poised for Technical ComebackRisk Controlled Picks With Real Returns Outlined - beatles.ru
Published on: 2025-08-11 02:04:05 - metal.it
Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate - MSN
Published on: 2025-08-10 19:02:24 - metal.it
Earnings Beat: Amneal Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - ca.finance.yahoo.com
Amneal 2025 Q2 Earnings Strong Performance as Net Income Surges 112% - AInvest
Amneal (AMRX) Q2 EPS Jumps 56% - AOL.com
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Amneal Pharma Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals Q2 2025 Earnings: EPS Beats Estimates, Revenue Falls Short - AInvest
Amneal: Q2 Earnings Snapshot - New Haven Register
Amneal Pharmaceuticals Inc (AMRX) Q2 2025 Earnings Call Highlights: Strong Growth and Raised ... By GuruFocus - Investing.com Canada
Amneal Pharma’s Optimistic Q2 Earnings Call Highlights - TipRanks
Amneal Pharmaceuticals' 2025Q2 Earnings Call: Key Contradictions on RYTARY, CREXONT, and Margin Strategies - AInvest
AMNEAL PHARMACEUTICALS Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast - Investing.com
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast By Investing.com - Investing.com Canada
Amneal Pharmaceuticals Stock Rises Amid Growth Signals - TipRanks
Amneal Pharmaceuticals shares rise 5.53% intraday after revising earnings guidance and raising fiscal 2025 outlook. - AInvest
Transcript : Amneal Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Amneal Raises Outlook Even As Revenue Falls Short - Finimize
Knight Therapeutics Submits CREXONT Marketing Authorization Application in Mexico - AInvest
Amneal Pharmaceuticals Lifts Annual Earnings Outlook As Q2 Net Income Surges; Pre-Market Stock Up - Nasdaq
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals Surpasses Q2 Earnings ExpectationsNews and Statistics - IndexBox
Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2025 - MarketScreener
Amneal Pharma A earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Amneal Pharmaceuticals beats Q2 estimates, raises full-year outlook - Investing.com
Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets - Yahoo Finance
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q2 Revenue $724.5M, vs. FactSet Est of $744.6M - MarketScreener
Amneal Pharmaceuticals Reports Strong Q2 2025 Results and Raises Full Year Guidance Following Successful Debt Refinancing - Quiver Quantitative
Amneal Reports Second Quarter 2025 Financial Results - GlobeNewswire
Amneal Pharmaceuticals' Q2 revenue misses estimates - MarketScreener
Amneal Pharmaceuticals Set to Announce Earnings Amid Market ChallengesNews and Statistics - IndexBox
Is There Enough Volume to Lift Amneal Pharmaceuticals Inc.Capital Preservation Forecast Insight Strategy - beatles.ru
Amneal Earnings: What To Look For From AMRX - Yahoo Finance
How does Amneal Pharmaceuticals Inc. compare to its industry peersRapid growth opportunities - Jammu Links News
How many analysts rate Amneal Pharmaceuticals Inc. as a “Buy”Consistent triple returns - Jammu Links News
What is Amneal Pharmaceuticals Inc. company’s growth strategyAccelerated profit realization - Jammu Links News
Is Amneal Pharmaceuticals Inc. a good long term investmentFree Wealth Management Insights - Jammu Links News
What analysts say about Amneal Pharmaceuticals Inc. stockStay informed with daily expert analysis - Jammu Links News
How strong is Amneal Pharmaceuticals Inc. company’s balance sheetExceptional profit velocity - Jammu Links News
What makes Amneal Pharmaceuticals Inc. stock price move sharplyTransform your portfolio with high-yield stocks - Jammu Links News
1.29%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):